financetom
Business
financetom
/
Business
/
Equinix, Digital Realty Trust to Benefit From Robust Growth Tailwinds, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Equinix, Digital Realty Trust to Benefit From Robust Growth Tailwinds, Morgan Stanley Says
Oct 16, 2025 9:00 AM

11:24 AM EDT, 10/16/2025 (MT Newswires) -- Equinix ( EQIX ) and Digital Realty Trust ( DLR ) are set to benefit from strong industry growth drivers, including rising AI inference activity and continued enterprise migration to hybrid multi-cloud environments, Morgan Stanley said in a note Thursday.

Both data center operators are expected to see long-term support from rising artificial intelligence inference activity as well as trends such as digital transformation, enterprise migration to hybrid multi-cloud environments, and global data growth, the brokerage said.

Morgan Stanley noted, however, that monetizing each operator's present development pipeline will be critical to equity performance, though both companies appear to have strong access to power availability.

The investment firm acknowledged that the "substantial capital committed to building out global data center capacity creates risk of long-term over-supply," but added that "near-term demand signals remain strong."

Morgan Stanley started coverage of Equinix ( EQIX ) with an overweight rating and $950 price target, reflecting confidence in its long-term guidance, network effects, and potential for multiple re-rating as demand strengthens. It initiated coverage of Digital Realty ( DLR ) with an equal-weight rating and $195 price target.

The brokerage said Digital Realty's ( DLR ) equal-weight rating indicates its "more conservative forecast" compared with Street estimates due to "lower visibility into commencement timing and quarterly AI bookings."

Price: 829.27, Change: +7.03, Percent Change: +0.85

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Standex International Insider Bought Shares Worth $490,000, According to a Recent SEC Filing
Standex International Insider Bought Shares Worth $490,000, According to a Recent SEC Filing
Mar 11, 2026
02:46 PM EST, 02/04/2026 (MT Newswires) -- Andy L Nemeth, Director, on February 04, 2026, executed a purchase for 2,000 shares in Standex International ( SXI ) for $490,000. Following the Form 4 filing with the SEC, Nemeth has control over a total of 8,639 common shares of the company, with 8,639 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/310354/000031035426000002/xslF345X05/form4.xml Price: 242.97,...
Latin America's oil leaders to outcompete Venezuela through 2030, Rystad says
Latin America's oil leaders to outcompete Venezuela through 2030, Rystad says
Mar 11, 2026
MEXICO CITY, Feb 4 (Reuters) - Argentina, Guyana and Brazil will lead Latin American oil production growth in 2026, adding ‌more than 700,000 barrels per day ​and outcompeting Venezuela through at least ‍2030, according to Rystad ⁠Energy analysis. KEY ⁠CONTEXT -- Latin America's oil production is ‌forecast to exceed ​8.8 million barrels per day this year, Rystad Energy ⁠said in...
Commercial Metals Insider Sold Shares Worth $2,003,249, According to a Recent SEC Filing
Commercial Metals Insider Sold Shares Worth $2,003,249, According to a Recent SEC Filing
Mar 11, 2026
02:45 PM EST, 02/04/2026 (MT Newswires) -- Jennifer J Durbin, Former Chief Human Resources and Communications Officer, on February 03, 2026, sold 25,050 shares in Commercial Metals ( CMC ) for $2,003,249. Following the Form 4 filing with the SEC, Durbin has control over a total of 52,880 common shares of the company, with 52,880 shares held directly. SEC Filing:...
India's Lupin Launches Seizure Drug Bioequivalent to Supernus Pharmaceuticals' Trokendi XR
India's Lupin Launches Seizure Drug Bioequivalent to Supernus Pharmaceuticals' Trokendi XR
Mar 11, 2026
02:45 PM EST, 02/04/2026 (MT Newswires) -- India-based pharmaceutical company Lupin said Wednesday it has launched a drug that is bioequivalent to Supernus Pharmaceuticals' ( SUPN ) Trokendi XR in the US. Lupin's Topiramate extended-release capsules were launched after the US Food and Drug Administration approved its Abbreviated New Drug Application, the company said. The drug is approved for partial-onset...
Copyright 2023-2026 - www.financetom.com All Rights Reserved